ES2179880T3 - Tratamiento del cancer utilizando un mutante del hsv. - Google Patents

Tratamiento del cancer utilizando un mutante del hsv.

Info

Publication number
ES2179880T3
ES2179880T3 ES95927034T ES95927034T ES2179880T3 ES 2179880 T3 ES2179880 T3 ES 2179880T3 ES 95927034 T ES95927034 T ES 95927034T ES 95927034 T ES95927034 T ES 95927034T ES 2179880 T3 ES2179880 T3 ES 2179880T3
Authority
ES
Spain
Prior art keywords
mutant
hsv
cancer treatment
gen
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95927034T
Other languages
English (en)
Inventor
Alasdair Roderick Maclean
Susanne Moira Brown
Nigel William Fraser
Bruce Paul Randazzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Wistar Institute of Anatomy and Biology
Original Assignee
University of Glasgow
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10759079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2179880(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Glasgow, Wistar Institute of Anatomy and Biology filed Critical University of Glasgow
Application granted granted Critical
Publication of ES2179880T3 publication Critical patent/ES2179880T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

USO COMO AGENTE ANTICANCERIGENO DE UN VIRUS DE HERPES SIMPLE MUTANTE DE FORMA QUE EL VIRUS MUTANTE INCLUYE UNA MODIFICACION EN EL GEN {PS}34.5 DE LA ZONA DE REPETICION LARGA (R{SUB,L}) DE FORMA QUE EL GEN {PS}34.5 NO SEA FUNCIONAL, FABRICACION DE MEDICAMENTOS Y METODOS DE COMPROBAR EL CANCER EN MAMIFEROS UTILIZANDO EL MUTANTE DE HSV.
ES95927034T 1994-07-29 1995-07-28 Tratamiento del cancer utilizando un mutante del hsv. Expired - Lifetime ES2179880T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9415320A GB9415320D0 (en) 1994-07-29 1994-07-29 Cancer treatment

Publications (1)

Publication Number Publication Date
ES2179880T3 true ES2179880T3 (es) 2003-02-01

Family

ID=10759079

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95927034T Expired - Lifetime ES2179880T3 (es) 1994-07-29 1995-07-28 Tratamiento del cancer utilizando un mutante del hsv.

Country Status (12)

Country Link
US (3) US7674468B2 (es)
EP (2) EP0773785B1 (es)
JP (2) JP4321723B2 (es)
AT (1) ATE219681T1 (es)
AU (1) AU3119995A (es)
CA (1) CA2196315C (es)
DE (1) DE69527204T2 (es)
DK (1) DK0773785T3 (es)
ES (1) ES2179880T3 (es)
GB (1) GB9415320D0 (es)
PT (1) PT773785E (es)
WO (1) WO1996003997A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
AU1550797A (en) * 1996-01-25 1997-08-20 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
MXPA01010393A (es) 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.
WO2001016331A1 (en) * 1999-08-31 2001-03-08 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
ES2320239T3 (es) 1999-09-17 2009-05-20 Wellstat Biologics Corporation Virus oncolitico.
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
ATE508635T1 (de) 2001-03-27 2011-05-15 Catherex Inc Virusvektoren und ihre verwendung bei therapeutischen methoden
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US7582614B2 (en) 2003-03-07 2009-09-01 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
EP1606411B1 (en) 2003-03-27 2008-12-10 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and use thereof
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
CN101137748B (zh) 2005-03-07 2011-12-14 罗巴斯研究机构 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
CA2921063C (en) 2006-09-15 2020-01-28 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US10821140B2 (en) * 2016-04-22 2020-11-03 Immvira Co., Limited Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
EP4209485A4 (en) * 2020-09-04 2025-02-19 Innovstone Therapeutics Limited ASSOCIATES WITH ANTI-TUMOOR ACTIVITY AND USE THEREOF

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
CA2132976C (en) * 1992-03-31 2003-12-30 Bernard Roizman Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
US6139834A (en) * 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
JPH11513390A (ja) 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
AU1550797A (en) 1996-01-25 1997-08-20 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
WO2007026146A1 (en) 2005-08-30 2007-03-08 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
EP2016182B8 (en) 2006-05-11 2015-09-02 Virttu Biologics Limited Mutant hsv, materials and methods for generation of mutant hsv
WO2008099189A2 (en) 2007-02-16 2008-08-21 Crusade Laboratories Limited Herpes simplex viruses and methods of viral replication
GB0714578D0 (en) 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Also Published As

Publication number Publication date
JP2008037869A (ja) 2008-02-21
WO1996003997A3 (en) 1996-05-02
DE69527204D1 (de) 2002-08-01
US20050260169A1 (en) 2005-11-24
DE69527204T2 (de) 2003-02-20
AU3119995A (en) 1996-03-04
WO1996003997A2 (en) 1996-02-15
GB9415320D0 (en) 1994-09-21
JP4321723B2 (ja) 2009-08-26
EP0773785B1 (en) 2002-06-26
EP1192948A2 (en) 2002-04-03
JPH10503766A (ja) 1998-04-07
CA2196315A1 (en) 1996-02-15
US8067012B2 (en) 2011-11-29
US20120141418A1 (en) 2012-06-07
PT773785E (pt) 2002-11-29
CA2196315C (en) 2010-02-09
US7674468B2 (en) 2010-03-09
EP0773785A2 (en) 1997-05-21
US20100172872A1 (en) 2010-07-08
ATE219681T1 (de) 2002-07-15
DK0773785T3 (da) 2002-10-07
EP1192948A3 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
ES2179880T3 (es) Tratamiento del cancer utilizando un mutante del hsv.
ES2077869T3 (es) Policitraconimidas y poliitaconimidas que contienen poli(sulfuro).
ES2044116T3 (es) Clavija de union de huesos.
LUC00032I2 (es)
TR199801603T2 (xx) �ki par�a yivli k�l�f.
ATE415915T1 (de) Vorrichtungen zur behandlung von wirbelkoerpern
JPS5244933A (en) Wheeled chair
ES2134277T3 (es) Producto de organo-aluminoxi y uso.
FI933656A0 (fi) 2,4-diaminokinazolinderivat, som foerstaerker antitumoeraktivitet
ES2149264T3 (es) Agente terapeutico para el tratamiento de melanomas.
ES2059674T3 (es) Uso de una composicion como un producto cosmetico.
NL191812B (nl) Hogedrukgasontladingslamp en armatuur voorzien van die lamp.
MX9303376A (es) Utilizacion de metilhidroxietil- o metilhidroxipropil-(eteres de celulosa)carboximetilados.
ES2168285T3 (es) Agentes endoparasiticidas que contienen praziquantel y epsiprantel.
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
ES2187555T3 (es) Panel de revestimiento.
ES2187504T3 (es) Vectores no oncovirales, basados en el vmmp, con encapsidacion defectuosa.
AR034071A1 (es) Combinaciones antineoplasicas
BR9907025B1 (pt) Polissacarídeos sintéticos e uso dos mesmos
IT1319275B1 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo.
CY1104971T1 (el) Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους
ES2179302T3 (es) Formas galenicas y sus utilizaciones.
ES2039251T3 (es) Tratamiento del cabello.
ES2173180T3 (es) Derivados del mercaptoacetilamida hipocolesterolemicos, antiateroescleroticos e hipotrigliceridemicos.
JPS528686A (en) Ultraviolet light irradition device